-
Article
Should systematic prostatic biopsies be discontinued?
The use of systematic biopsies in addition to targeted biopsies is based on multiple studies showing that 15–20% of “clinically significant” cancers are missed on targeted biopsies. Concern about these ‘missed...
-
Article
Overdiagnosis in urologic cancer
Cancer, which historically was diagnosed at late and incurable stages, has expanded to a heterogeneous group of conditions that vary from clinically insignificant to rapidly aggressive and lethal. This evoluti...
-
Article
The ‘C’ Words: parallels and analogies between Prostate Cancer and Covid-19
-
Article
Sco** review: hotspots for COVID-19 urological research: what is being published and from where?
Contemporary, original research should be utilised to inform guidelines in urology relating to the COVID-19 pandemic. This comprehensive review aimed to: identify all up-to-date original publications relating ...
-
Article
Impact of COVID-19 on medical education: introducing homo digitalis
To determine how members of the Société Internationale d’Urologie (SIU) are continuing their education in the time of COVID-19.
-
Article
Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion biopsy, MRUS fusion biopsy) —literature review
To compare the detection rate of clinically significant cancer (CSCa) by magnetic resonance imaging-targeted biopsy (MRI-TB) with that by standard systematic biopsy (SB) and to evaluate the role of MRI-TB as a...
-
Article
Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer
Androgen deprivation therapy (ADT) is still a mainstay of treatment for advanced prostate cancer. Continuous ADT causes considerable patient morbidity including sexual dysfunction, poor mood and physical capac...
-
Article
Surveillance after prostate focal therapy
Long-term outcomes from large cohorts are not yet available upon which to base recommended follow-up protocols after prostate focal therapy. This is an updated summary of a 2015 SIU-ICUD review of the best ava...
-
Article
Open AccessAndrogen-targeted therapy in men with prostate cancer: evolving practice and future considerations
Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances. These include approval of new therapies...
-
Article
Open AccessThe Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation
Refinement of parameters defining prostate cancer (PC) prognosis are urgently needed to identify patients with indolent versus aggressive disease. The Canadian Prostate Cancer Biomaker Network (CPCBN) consists...
-
Article
Open AccessA single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA ‘grey zone’
To determine the clinical performance of a blood-based test for clinically significant (CS) prostate cancer (PCa) (grade group ≥ 2) intended for use in men with prostate serum antigen levels in the ‘grey zone’...
-
Chapter
Research Questions in Active Surveillance
There are many unanswered questions and unmet needs regarding the optimal management of men on active surveillance and many compelling research opportunities. These include the use of molecular genetics, imagi...
-
Chapter
Cancer Overdiagnosis and Overtreatment
Cancer, which used to be diagnosed at late and incurable stages, has expanded to a heterogeneous group of conditions that vary from clinically insignificant to rapidly aggressive and lethal. This evolution is ...
-
Chapter
Surveillance at the Margins: Management of High-Volume Gleason 6, PSA > 10, or Gleason 3 + 4
Purpose of review: Active surveillance is now widely utilized for the management of low-risk prostate cancer (PCa). The limit of surveillance for men with intermediate-risk cancer is controversial. While there...
-
Article
Active Surveillance for Intermediate Risk Prostate Cancer
Active surveillance is now widely utilized for the management of low-risk prostate cancer (PCa). The limits of surveillance for men with intermediate risk cancer are controversial. While there is a broad conse...
-
Article
Open AccessSemantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure
Active surveillance (AS) is broadly described as a management option for men with low-risk prostate cancer, but semantic heterogeneity exists in the literature...
-
Chapter
Low-Risk Prostate Cancer in North America: Rationale, Uptake, and Limitations of Active Surveillance and Opportunities for Focal Therapy
Active surveillance (AS) has emerged as the standard of care for low-risk, low-volume prostate cancer. Herein we examine the rationale for AS, considering the tumor biology and available evidence on the almost...
-
Article
Management of low- and intermediate-risk prostate cancer
-
Article
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers
Low-risk prostate cancer is found in about half of newly diagnosed men subjected to PSA screening.
-
Article
Active Surveillance for Low-Risk Prostate Cancer
There is ample evidence that low risk and many cases of low-/intermediate-risk prostate cancer, are indolent, have little or no metastatic potential, and do not pose a threat to the patient in his lifetime. Ma...
